Concepedia

Author

Anne Schuind

GlaxoSmithKline (Belgium)ORCID

Also Known As

A Schuind, A. Schuind, Anne E. Schuind, Anne E Schuind, Anne E. Schuind, Anne Schuind, Christian Schubert, G Dubin

105

Publications

7.2K

Citations

33

H-Index

62

Concepts

All Affiliations

GlaxoSmithKline (Belgium)GlaxoSmithKline (United States)Dalhousie UniversityJohannes Gutenberg University MainzWestmead Institute for Medical Research
AS

About

Anne Schuind is an author at GlaxoSmithKline (Belgium) specializing in medicine, vaccination, and vaccine safety.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

27

4.8K

2

Epidemiology

7

8

362

3

Public Health

5

5

184

4

Health Sciences

1

1

24

5

Allergy

1

1

91

Anne Schuind

×

62

Publications

6.3K

Citations

32

H-Index

YearCitations

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler,

The Lancet

2004

1.6K

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler,

The Lancet

2006

1.6K

Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

Mark H. Einstein, Mira Baron, Myron J. Levin,

Human Vaccines

2009

396

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman İlhan, Won Sik Lee,

The Lancet Infectious Diseases

2019

242

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson,

Human Vaccines

2011

194

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

N. De Carvalho, Júlio César Teixeira, Cecília Roteli-Martins,

Vaccine

2010

169

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

Mark H. Einstein, Mira Baron, Myron J. Levin,

Human Vaccines

2011

114

Comparative Evaluation of Safety and Immunogenicity of Two Dosages of an Oral Live Attenuated Human Rotavirus Vaccine

Penelope H. Dennehy, Rebecca C. Brady, Scott A. Halperin,

The Pediatric Infectious Disease Journal

2005

101

Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b - PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine

Fred Zepp, H. J. Schmitt, Achim Kaufhold,

European Journal of Pediatrics

1996

92

A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data

Jane Gidudu, Katrin Kohl, Scott A. Halperin,

Vaccine

2008

91

Page 1